open access

Vol 93, No 12 (2022)
Research paper
Published online: 2022-02-10
Get Citation

Ischemia modified albumin levels in intrauterine growth restriction: levels are increased in fetal cord blood but not in maternal blood

Ceren Gölbaşı1, Hakan Gölbaşı2, Ceysu Kocahakimoğlu Gültekin2, Varol Gülseren2, Merve Zeytinli Akşit3, Burak Bayraktar2, Ayfer Çolak3, Cüneyt Eftal Taner2
·
Pubmed: 35156698
·
Ginekol Pol 2022;93(12):993-998.
Affiliations
  1. Department of Obstetrics and Gynecology, Izmir Tınaztepe University Faculty of Medicine, Izmir, Turkey
  2. Department of Obstetrics and Gynecology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey, Izmir
  3. Department of Biochemistry, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey

open access

Vol 93, No 12 (2022)
ORIGINAL PAPERS Obstetrics
Published online: 2022-02-10

Abstract

Objectives: In this study, our aim was to determine the differences between intrauterine growth restriction (IUGR) and normal birth weight fetuses in terms of ischemia modified albumin (IMA) levels. For this purpose, we measured ischemia modified albumin levels in the cord blood of fetuses and venous blood of mothers.

Material and methods: This study is a prospective study conducted at University of Health Sciences Tepecik Training and Research Hospital between January 2018 and December 2019. According to the inclusion/exclusion criteria, 227 patients were included in the study. Participants were divided into two groups according to the presence (patient group) or absence (control group) of intrauterine growth restriction (IUGR). In addition to routine parameters recorded during pregnancy, the IMA levels and Doppler USG findings of all participants were recorded.

Results: The mean cord blood serum IMA levels of the patient group were significantly elevated compared to controls (p = 0.038). Whereas mean maternal blood serum IMA levels were similar among groups (p = 0.453). The cord blood and mother blood serum IMA levels were not significantly different with regard to the presence or absence of perinatal asphyxia.

Conclusions: In the literature, studies evaluating IMA levels in the cord and maternal blood of IUGR fetuses are limited. In IUGR patients, IMA level is expected to increase and in our study, IMA levels were significantly increased but the presence of oxidative stress has not been found to affect IMA levels.

Abstract

Objectives: In this study, our aim was to determine the differences between intrauterine growth restriction (IUGR) and normal birth weight fetuses in terms of ischemia modified albumin (IMA) levels. For this purpose, we measured ischemia modified albumin levels in the cord blood of fetuses and venous blood of mothers.

Material and methods: This study is a prospective study conducted at University of Health Sciences Tepecik Training and Research Hospital between January 2018 and December 2019. According to the inclusion/exclusion criteria, 227 patients were included in the study. Participants were divided into two groups according to the presence (patient group) or absence (control group) of intrauterine growth restriction (IUGR). In addition to routine parameters recorded during pregnancy, the IMA levels and Doppler USG findings of all participants were recorded.

Results: The mean cord blood serum IMA levels of the patient group were significantly elevated compared to controls (p = 0.038). Whereas mean maternal blood serum IMA levels were similar among groups (p = 0.453). The cord blood and mother blood serum IMA levels were not significantly different with regard to the presence or absence of perinatal asphyxia.

Conclusions: In the literature, studies evaluating IMA levels in the cord and maternal blood of IUGR fetuses are limited. In IUGR patients, IMA level is expected to increase and in our study, IMA levels were significantly increased but the presence of oxidative stress has not been found to affect IMA levels.

Get Citation

Keywords

ischemia modified albumin (IMA); oxidative stress; intrauterine growth restriction (IUGR); cord blood; asphyxia

About this article
Title

Ischemia modified albumin levels in intrauterine growth restriction: levels are increased in fetal cord blood but not in maternal blood

Journal

Ginekologia Polska

Issue

Vol 93, No 12 (2022)

Article type

Research paper

Pages

993-998

Published online

2022-02-10

Page views

3552

Article views/downloads

476

DOI

10.5603/GP.a2021.0208

Pubmed

35156698

Bibliographic record

Ginekol Pol 2022;93(12):993-998.

Keywords

ischemia modified albumin (IMA)
oxidative stress
intrauterine growth restriction (IUGR)
cord blood
asphyxia

Authors

Ceren Gölbaşı
Hakan Gölbaşı
Ceysu Kocahakimoğlu Gültekin
Varol Gülseren
Merve Zeytinli Akşit
Burak Bayraktar
Ayfer Çolak
Cüneyt Eftal Taner

References (21)
  1. Sinha MK, Roy D, Gaze DC, et al. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004; 21(1): 29–34.
  2. Apple FS, Wu AHB, Mair J, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005; 51(5): 810–824.
  3. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol. 2006; 108(3): 410–411.
  4. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med. 2007; 25(7): 770–773.
  5. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers. 2008; 24(6): 311–317.
  6. Yarcı Gursoy A, Caglar GS, Demirtas S. Ischemia modified albumin in perinatology. Eur J Obstet Gynecol Reprod Biol. 2017; 210: 182–188.
  7. Lees CC, Stampalija T, Baschat A, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020; 56(2): 298–312.
  8. Fetal Growth Restriction. Obstetrics & Gynecology. 2021; 137(2): e16–e28.
  9. Toy H, Camuzcuoglu H, Arioz DT, et al. Serum prolidase activity and oxidative stress markers in pregnancies with intrauterine growth restricted infants. J Obstet Gynaecol Res. 2009; 35(6): 1047–1053.
  10. Iacovidou N, Briana DD, Boutsikou M, et al. Cord blood ischemia-modified albumin levels in normal and intrauterine growth restricted pregnancies. Mediators Inflamm. 2008; 2008: 523081.
  11. Rossi A, Bortolotti N, Vescovo S, et al. Ischemia-modified albumin in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2013; 170(2): 348–351.
  12. Ma Sg, Yu Wn, Jin Y, et al. Evaluation of serum ischemia-modified albumin levels in pregnant women with and without gestational diabetes mellitus. Gynecol Endocrinol. 2012; 28(11): 837–840.
  13. Gafsou B, Lefèvre G, Hennache B, et al. Maternal serum ischemia-modified albumin: a biomarker to distinguish between normal pregnancy and preeclampsia? Hypertens Pregnancy. 2010; 29(1): 101–111.
  14. Özdemir S, Kıyıcı A, Balci O, et al. Assessment of ischemia-modified albumin level in patients with recurrent pregnancy loss during the first trimester. Eur J Obstet Gynecol Reprod Biol. 2011; 155(2): 209–212.
  15. Use and Abuse of the Apgar Score. Pediatrics. 1996; 98(1): 141–142.
  16. Bhide A, Acharya G, Bilardo CM, et al. ISUOG practice guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol. 2013; 41(2): 233–239.
  17. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4): 311–315.
  18. Gugliucci A, Hermo R, Monroy C, et al. Ischemia-modified albumin levels in cord blood: a case-control study in uncomplicated and complicated deliveries. Clin Chim Acta. 2005; 362(1-2): 155–160.
  19. Guvendag Guven ES, Karcaaltincaba D, Kandemir O, et al. Cord blood oxidative stress markers correlate with umbilical artery pulsatility in fetal growth restriction. J Matern Fetal Neonatal Med. 2013; 26(6): 576–580.
  20. Cengiz H, Dagdeviren H, Kanawati A, et al. Ischemia-modified albumin as an oxidative stress biomarker in early pregnancy loss. J Matern Fetal Neonatal Med. 2016; 29(11): 1754–1757.
  21. Prefumo F, Gaze DC, Papageorghiou AT, et al. First trimester maternal serum ischaemia-modified albumin: a marker of hypoxia-ischaemia-driven early trophoblast development. Hum Reprod. 2007; 22(7): 2029–2032.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl